"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Descriptor ID |
D010190
|
| MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
| Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 1 | 5 |
| 1996 | 1 | 2 | 3 |
| 1997 | 4 | 0 | 4 |
| 1998 | 7 | 1 | 8 |
| 1999 | 3 | 0 | 3 |
| 2000 | 2 | 0 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 3 | 1 | 4 |
| 2003 | 3 | 2 | 5 |
| 2004 | 5 | 0 | 5 |
| 2005 | 19 | 0 | 19 |
| 2006 | 10 | 2 | 12 |
| 2007 | 13 | 2 | 15 |
| 2008 | 13 | 2 | 15 |
| 2009 | 22 | 2 | 24 |
| 2010 | 16 | 4 | 20 |
| 2011 | 23 | 4 | 27 |
| 2012 | 17 | 2 | 19 |
| 2013 | 19 | 1 | 20 |
| 2014 | 14 | 3 | 17 |
| 2015 | 13 | 0 | 13 |
| 2016 | 17 | 2 | 19 |
| 2017 | 22 | 3 | 25 |
| 2018 | 23 | 4 | 27 |
| 2019 | 25 | 1 | 26 |
| 2020 | 21 | 1 | 22 |
| 2021 | 22 | 1 | 23 |
| 2022 | 19 | 0 | 19 |
| 2023 | 22 | 1 | 23 |
| 2024 | 17 | 2 | 19 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2025 Feb 01; 160(2):172-180.
-
Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist. 2025 Jan 17; 30(1).
-
Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. Cancer Discov. 2025 Jan 13; 15(1):162-178.
-
Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Nat Cancer. 2025 Jan; 6(1):123-144.
-
OSBPL3 modulates the immunosuppressive microenvironment and predicts therapeutic outcomes in pancreatic cancer. Biol Direct. 2025 Jan 09; 20(1):5.
-
Lead time trajectory of blood-based protein biomarkers for detection of pancreatic cancer based on repeat testing. Cancer Lett. 2025 Mar 01; 612:217450.
-
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2025 Jan 07; 39(1-2):36-63.
-
FOXM1-Cx31 Axis Drives Pancreatic Cancer Stem Cell-Like Properties and Chemoresistance. Mol Carcinog. 2025 Mar; 64(3):565-579.
-
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nat Commun. 2024 Dec 30; 15(1):10743.
-
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study. Clin Cancer Res. 2024 Dec 16; 30(24):5559-5567.